Envoy Medical Q3 Loss Narrows to $5.2M; Cash $14.6M as PMA Module Two Filed
COCH sits 96% above its 52-week low of $3.625.
Summary
Envoy Medical reported a Q3 2026 net loss of $5.2 million ($0.50/share) on $66 thousand of revenue, with $14.6 million of cash left. Clinically, all 56 pivotal-trial patients passed six-month follow-up and the second of four PMA modules was submitted to FDA.
Key Events · Earnings and Guidance · COCH
-
Q3 Loss Narrows, Cash Falls to $14.6M
Net loss attributable to common stockholders was $5,240 thousand, or $0.50 per share, versus $7,747 thousand ($3.55) a year earlier. Cash stood at approximately $14,570 thousand at September 30, 2026, against $16,547 thousand of cash used in operations over the first nine months.
-
Second PMA Module Submitted to FDA
The company filed the second of four planned modules of its modular PMA for the Acclaim cochlear implant after quarter end. The final module, containing final clinical trial data, is planned a few months after all Stage 2 participants complete 12-month data collection early in Q2 2027.
-
All 56 Trial Patients Pass Six-Month Mark
The pivotal trial surpassed the six-month follow-up visit milestone for all 56 patients. The primary efficacy endpoint is evaluated on 12-month data; the first 10 Stage 1 participants showed a mean CNC word score of 53.2% at 12 months versus a 15.2% baseline.
-
Prior Equity Raise Drove Share Count Up
Class A shares outstanding rose to 7,744,488 at September 30, 2026 from 2,893,495 at December 31, 2025, reflecting $29,997 thousand of gross proceeds from a common/pre-funded warrant/Series A warrant issuance in the first nine months, net of $2,215 thousand of offering costs.
Analysis · COCH · Industrial Applications And Services
The quarter itself is small in dollar terms — revenue of $66 thousand against a $5.2 million net loss — so the numbers are not what moves this stock. What matters is the combination of a shrinking cash balance and steady clinical progress: $14.6 million of cash at September 30 against roughly $5.5 million of quarterly operating burn leaves the company dependent on raising more money before its PMA is filed. Against that backdrop, the second of four PMA modules going to FDA and all 56 pivotal-trial patients passing the six-month follow-up keep the approval timeline intact, with final-module submission planned a few months after 12-month data collection completes early in Q2 2027. The equity raise already executed in the first nine months ($30.0 million gross, $2.2 million of costs) is why shares outstanding rose to 7.74 million from 2.89 million at year-end 2025 — dilution already taken, not new.
How filings like this one have moved
In the 30 days to Nov 5, 2026, 33.4% of the 2397 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COCH was trading at $7.12 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $55.1M. The 52-week trading range was $3.63 to $9.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.